Comments to "No impact of anti-Rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis"

Osteoporos Int. 2023 Mar;34(3):617-623. doi: 10.1007/s00198-022-06644-z. Epub 2022 Dec 23.

Authors

Shuman Yang¹, Ziyu Dong¹, Bo Kan²

Affiliations

¹ Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin, China.
² Department of Clinical Laboratory, The Second Hospital of Jilin University, Jilin University, Changchun, Jilin, China. kanbo234@jlu.edu.cn.

PMID: 36550210
DOI: 10.1007/s00198-022-06644-z

No abstract available

Publication types

Systematic Review
Meta-Analysis
Letter
Comment

MeSH terms

Bone Density
Cardiovascular Diseases* / etiology
Cardiovascular Diseases* / prevention & control
Female
Heart Disease Risk Factors
Humans
Ligands
Osteoporosis, Postmenopausal* / drug therapy
Parathyroid Hormone
RANK Ligand
Risk Factors

Substances

RANK Ligand
Ligands
Parathyroid Hormone